Quantitative characterization of cellular membrane-receptor heterogeneity through statistical and computational modeling

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Weddell, Jared C ^a   Imoukhuede, P I ^a  

^a University of Illinois at Urbana Champaign   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MEMBRANE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; CELL SURFACE RECEPTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CELL SURFACE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MALE; MATHEMATICAL MODEL; MOUSE; NONHUMAN; PREDICTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; STATISTICAL MODEL; TUMOR CELL; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; CELL MEMBRANE; COMPUTER SIMULATION; DRUG EFFECTS; ENDOTHELIUM CELL; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL MEMBRANE; COMPUTER SIMULATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84901335239     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097271     Document Type: Article

References (76)

1. Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, et al. (2011) Role of intratumoural heterogeneity in cancer drug resistance: Molecular and clinical perspectives. EMBO Mol Med 4: 675-684.
2. He B, Baird R, Butera R, Datta A, George S, et al. (2013) Grand challenges in interfacing engineering with life sciences and medicine. IEEE T Bio-Med Eng 60: 589-598.
3. Gabhann F, Peirce SM (2010) Collateral capillary arterialization following arteriolar ligation in murine skeletal muslce. Microcirculation 17: 333-347.
4. M, Hendriks L, Van Broeckhoven C (1996) The presenilin genes: A new gene family involved in alzheimer disease pathology. Hum Mol Genet 5 Spec No: 1449-1455.
5. Brabander H, van Hende J, Batjoens P, Hendriks L, Raus J, et al. (1994) Endogenic nortestosterone in cattle? Analyst 119: 2581-2585.
6. JD (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404-2407.
7. Y, Kawabata I, Sobue K, Okabe S (2005) Determination of absolute protein numbers in single synapses by a GFP-based calibration technique. Nat Meth 2: 677-684.
8. CS, Jensen K, Sokolova I, Wang D, Li M, et al. (2002) Number, density, and surface/cytoplasmic distribution of GABA transporters at presynaptic structures of knock-in mice carrying GABA transporter subtype 1-green fluorescent protein fusions. J Neurosci 22: 10251-10266.
9. WD, Napier SL, Burdick MM, Schnaar RL, Sackstein R, et al. (2006) Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J 20: 337-339.
10. PI, Popel AS (2011) Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Experimental Cell Research 317: 955-965.
11. PI, Popel AS (2012) Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One 7: e44791.
12. PI, Dokun AO, Annex BH, Popel AS (2013) Endothelial cell-by-cell profiling reveals temporal dynamics of VEGFR1 and VEGFR2 membrane-localization following murine hindlimb ischemia. Am J Physiol Heart Circ Physiol 304: H1085-93.
13. PI, Popel AS (2014) Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Medicine 3: 225-44.
14. SB, Bishop JE, Abrams B, Maino VC, Ward AJ, et al. (1997) QuantiBRITE: A new standard for PE fluorescence quantitation. BD Biosciences 23-3496-00.
15. KK, Joe ET, Iyer SB (2001) Performance evaluation of quantiBRITE phycoerythrin beads. Cytometry 45: 250-258.
16. -Montiel FT, Imoukhuede PI (2013) Engineering quantum dot calibration standards for quantitative fluorescent profiling. J Mater Chem B 1: 6434-6441.
17. MJ, Ferbas J (2008) Mixture modeling approach to flow cytometry data. Cytom Part A 73A: 421-429.
18. Meur N (2013) Computational methods for evaluation of cell-based data assessment - bioconductor. Curr Opin Biotech 24: 105-111.
19. B, Eichler-Jonsson C, Gilles ED, Muller G (2002) Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nature Biotech 20: 370-375.
20. A, Kuo SC, Lauffenburger DA (1993) Heterogeneity and probabilistic binding contributions to receptor-mediated cell detachment kinetics. Biophys J 65: 243-252.
21. MO, Wu FT, Mac Gabhann F, Popel AS (2008) A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol 2.
22. MO, Wu FT, Mac Gabhann F, Popel AS (2010) Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model. Cancer Res 70: 9886-9894.
23. SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS (2011) Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol 5: 193.
24. CK, Li J, Murga M, Harris AL, Tosato G (2005) Up-regulation of the notch ligand delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107: 931-939.
25. AM, Wang SJ, Taylor AC, Aitkenhead M, Hughes CC (2001) The basic helix-loop-helix transcription factor HESR1 regulates endothelial cell tube formation. J Biol Chem 276: 6169-6176.
26. C, Ley C, Klein O, Bernard P, Licata L (2013) Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol 49: 764-766.
27. G, Peel D (2004) Finite mixture models. Canada: John Wiley & Sons.
28. X, Zhang S, Zhao H, Cooper RS (2002) Association mapping, using a mixture model for complex traits. Genet Epidemiol 23: 181-196.
29. L, Gove JH, Liu C, Leak WB (2001) A finite mixture of two weibull distributions for modeling the diameter distributions of rotated-sigmoid, uneven-aged stands. Can J Forest Res 31: 1654-1659.
30. -Trieglaff O, Machtejevans E, Reinert K, Schluter H, Thiemann J, et al. (2009) Statistical quality assessment and outlier detection for liquid chromatography-mass spectrometry experiements. BioData Mining 2.
31. SH, Pak D, Choi J, Cho HJ (2012) Outlier detection using projection quantile regression for mass spectrometry data with low replication. BMC Res Notes 5: 236.
32. D, Chinnaiyan AM (2009) Genomic outlier profile analysis: Mixture models, null hypotheses, and nonparametric estimation. Biostatistics 10: 60-69.
33. A, Brinkman RR (2009) A survey of flow cytometry data analysis methods. Adv Bioinformat 2009: Article ID 584603.
34. E, Roederer M, Cossarizza A (2010) Data analysis in flow cytometry: The future just started. Cytom Part A 77A: 705-713.
35. N, Nikolic R, Hoos HH, Brinkman RR (2011) Rapid cell population identification in flow cytometry data. Cytom Part A 79A: 6-13.
36. G, Zimmerman N, Moore W, Parks D, Meehan S, et al. (2009) Automatic clustering of flow cytometry data with density-based merging. Adv Bioinformat 2009: Article ID 686759.
37. M, Treister A, Moore W, Herzenberg LA (2001) Probability binning comparison: A metric for quantitating univariate distribution differences. Cytometry 45: 37-46.
38. JF, Birkes D, Lee Y (1997) Characterizing sums of squares by their distributions. Am Stat 51: 55-58.
39. A, Kikutani H (2013) Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev Immunol 13: 802-814.
40. G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, et al. (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424: 391-397.
41. WH, Popel AS, Mac Gabhann F (2013) Computational model of Gab1/2-dependent VEGFR2 pathway to akt activation. PLoS One 8: e67438.
42. S, Oda N, Abe M, Terai Y, Ito M, et al. (2000) Roles of two VEGF receptors, flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19: 2138-2146.
43. J, Bian D, Mahanivong C, Cheng RK, Zhou W, et al. (2004) p38 mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J Biol Chem 279: 50446-50454.
44. A, Mirshahi P, Benabbou N, Azzazene D, Bordu C, et al. (2009) Vascular endothelial growth factor receptor-1 (VEGFR-1) expression in human corneal fibroblast decreased with age. Mol Vis 15: 1997-2007.
45. A, Iwai S, Sakurai Y, Ito M, Shitara K, et al. (2001) Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97: 785-791.
46. M (2006) Vascular endothelial growth factor receptor-1 (VEGFR-1/flt-1): A dual regulator for angiogenesis. Angiogenesis 9: 225-230.
47. M, Gerlach M, Gerlach H, Brett J, Wang F, et al. (1990) Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172: 1535-1545.
48. N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676.
49. AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
50. JB, Kappas NC, Ellerstrom C, DiPaola FW, Bautch VL (2004) The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood 103: 4527-4535.
51. G, Ochiya T, Terada M, Yoshida T (2000) Mouse flt-1 promoter directs endothelial-specific expression in the embyroid body model of embryogenesis. Biochem Bioph Res Co 276: 1089-1099.
52. T, Amano H, Ito Y, Eshima K, Minamino T, et al. (2014) Vascular endothelial growth factor receptor 1 signaling facilitates gastric ulcer healing and angiogenesis through the upregulation of epidermal growth factor expression on VEGFR1(+)CXCR4 (+) cells recruited from bone marrow. J Gastroenterol 49: 455-469.
53. S, Nakamura K, Iwai S, Murakami M, Itoh T, et al. (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung specific metastasis. Cancer Cell 2: 289-300.
54. K, Zhu Y, Sun Y, Mao XO, Xie L, et al. (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. PNAS 99: 11946-11950.
55. MH, Tripps WKC, Feldmann RE Jr, Kuschinsky W (2003) Expression of vascular endothelial growth factor and its receptors in rat neural stem cells. Neurosci Lett 344: 165-168. (Pubitemid 36694669)
56. Gabhann F, Popel AS (2007) Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: A computational model of human skeletal muscle. Am J Physiol Heart Circ Physiol 292: H459.
57. M, Booth PJ (2004) Insertion kinetics of a denatured a helical membrane protein into phospholipid bilayer vesicles. J Mol Biol 344: 1109-1121.
58. JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF (2010) Heterogeneity of the tumor vasculature. Semin Thromb Hemost 36: 321-331.
59. JA, Dvorak HF (2012) Heterogeneity of the tumor vasculature: The need for new tumor blood vessel type-specific targets. Clin Exp Metastasis 29: 657-662.
60. Bock K, Cauwenberghs S, Carmeliet P (2011) Vessel abnormalization: Another hallmark of cancer? molecular mechanisms and therapeutic implications. Curr Opin Genet Dev 21: 73-79.
61. EJ, Bautch VL (2013) Building blood vessels in development and disease. Curr Opin Hematol 20: 231-236.
62. DK, Ku CJ, Wichaidit C, Steininger RJ 3rd, Wu LF, et al. (2010) Patterns of basal signaling heterogeneity can distinguish celllular populations with different drug sensitivities. Mol Syst Biol 6: 369.
63. MD, Martinez ED, Wu LF, Altschuler SJ (2008) Characterizing heterogeneous cellular responses to perturbations. PNAS 105: 19306-19311.
64. Y SJ (1987) Self-phosphorylation of epidermal growth factor receptor: Evidence for a model of intermolecular allosteric activation. Biochem 26: 1434-1442.
65. I, Engel M, Levitzki A (1992) Kinetic model of the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF. J Biol Chem 267: 20638-20647.
66. H, Ewald JA, Dixon DA, Wiley HS (2003) An integrated model of epidermal growth factor receptor trafficking and signal transduction. Biophys J 85: 730-743.
67. K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1: 2005.0010.
68. WH, Popel AS, Mac Gabhann F (2013) Computational model of VEGFR2 pathway to ERK activation and modulation through receptor trafficking. Cell Signal 25: 2496-2510.
69. Gabhann F, Popel AS (2004) Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 286: H153-H164. (Pubitemid 38049475)
70. Gabhann F, Popel AS (2007) Dimerization of VEGF receptors and implications for signal transduction: A computational study. Biophys Chem 128: 125-139. (Pubitemid 46843440)
71. SD, Popel AS (2013) Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: Systems biology predictions. J Nat Cancer Institute 105: 802-811.
72. SD, Dhar M, Popel AS (2013) Compartment model predicts VEGF secretion and investigates the effects of VEGF Trap in tumor-bearing mice. Front Oncol 3: 196.
73. SD, Popel AS (2012) Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J 14: 500-509.
74. DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027.
75. LM, Hicklin DJ (2008) VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8: 579-591.
76. C, Mac Gabhann F, Popel AS (2007) Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 97: 978-985.